Molecular Quality Controls Market

Molecular Quality Controls Market by Product (Independent, Instrument Specific (PCR, DNA Sequencing)), Application (Infectious Diseases Diagnostic), Analyte Type, End User (Hospitals, Diagnostic Lab) – Global Forecast to 2026

Report Code: MD 6900 Feb, 2022, by marketsandmarkets.com

[275 Pages Report] The molecular quality controls market size is expected to grow from USD 164 million in 2021 to USD 226 million by 2026, at a CAGR of 6.7% during the forecast period. The growth of this market is primarily driven by factors such as the rising adoption of third-party quality controls, increasing number of accredited clinical laboratories, the rising demand for external quality assessment support, increasing government funding to support genomics projects, increasing demand for personalized medicines and declining costs of sequencing procedures and increasing prevalence of infectious diseases, cancer & genetic diseases.

In this report, the molecular quality control market is segmented based on product, analyte type, application, end user and region.

Molecular Quality Controls Market

To know about the assumptions considered for the study, download the pdf brochure

COVID-19 Impact on the Molecular Quality Control Market

COVID-19 is an infectious disease caused by the most recently discovered novel coronavirus. Largely unknown before the outbreak began in Wuhan (China) in December 2019, COVID-19 moved from a regional crisis to a global pandemic in just a few weeks. The World Health Organization (WHO) declared COVID-19 as a pandemic on March 11, 2020.

The COVID-19 pandemic negatively affected the sales of companies. Lockdowns resulting from the COVID-19 pandemic caused people to delay undergoing health check-ups, affecting the number of tests being performed and sales of reagents. However, a resurgence in testing numbers is seen as countries gradually ease restrictions on movement. With the COVID-19 pandemic, responding to infectious disease has become a pressing medical issue worldwide. In addition to developing vaccines and therapeutic drugs, there is a growing need for developing more precise and simple testing technologies and the expansion of testing structures. COVID-19 has also impacted the regulatory environment and practices, as governments and healthcare providers face unprecedented challenges. Regulatory authorities utilized methods to speed the approval of diagnostic products. Companies have also taken strategic developments to introduce COVID-19 rapid tests, sustain their revenues, and nullify the impact of COVID-19 on their operational capabilities.

Molecular Quality Control Market Dynamics

Drivers:  Increasing number of accredited clinical laboratories

Globally, the number of laboratory tests being conducted has increased owing to the rising burden of various diseases worldwide. To meet this demand, the number of laboratories in public as well as the private sector is increasing. In most countries, it is mandatory for clinical laboratories to secure accreditation from regulatory bodies such as the International Organization for Standardization (ISO) 15189:2012 and other similar standards to perform diagnostic tests. During the accreditation process, the respective authorities evaluate the quality system and competence of a laboratory based on specific standards.

In 2020, the number of total laboratory entities registered for CLIA accreditation increased to 286,396 as compared to 259,967 in 2017. Also, in 2018, 15,353 laboratories received CLIA accreditation by several accreditation organizations (Source: CLIA UPDATE – January 2020).

Restraints: Additional costs involved in quality control and budget constraints in hospitals and laboratories

Setting up a QC process in a clinical laboratory requires significant investments. Laboratories also need to maintain dedicated personnel to manage the QC system. Moreover, QC procedures incur similar costs, regardless of the volume of tests performed. Hence, the cost of adopting QC procedures is very high for clinical laboratories working with low volumes of diagnostic tests. This, coupled with budgetary constraints in many hospitals and laboratories in developed and developing economies, is expected to result in the lower adoption of QC practices.

Opportunities: Rising demand for multi-analyte control

Technological advancements have led to the development of a new range of multi-analyte and multi-instrument controls. These innovative controls consolidate multiple instrument-specific controls into a single control, thereby enabling clinical laboratories to cut down costs. In addition, these controls save the time involved in separate QC procedures for each individual analyte.

Several companies have also expanded their portfolio by adding new tests. For instance, in February 2020, Bio-Rad Laboratories (US) launched EDX RP Positive Run Control, the first multi-analyte control to target 22 analytes in a single vial, which can save laboratories time and space on their instruments. Also, in April 2020, Thermo Fisher Scientific (US) launched AcroMetrix Coronavirus 2019 (COVID-19) RNA Control to monitor and validate COVID-19 molecular diagnostic tests. The growing availability of such molecular quality controls for infectious diseases diagnostics and other applications is expected to support market growth in the coming years.

Challenges: Changing regulatory framework

Regulatory and legal requirements applied to IVD (including molecular diagnostics) in the US and European countries are becoming more stringent. In the US, IVD products are defined under 21 CFR 809 and regulated under guidelines like medical devices. The FDA released new FDA guidance documents. Under US federal regulations, device manufacturers must submit a 510 (k) application for any further modifications to a device. New applications may require software updates or new software installation in an existing device or any other changes made to these devices.

There are an estimated 1,00,000 laboratories in India, and because of low entry barriers, there is less reliance on molecular products quality with no quality assurance requirements mandate for molecular diagnostic testing procedures. Similarly, in Turkey, there is no accreditation system relevant to clinical laboratories, while in Argentina, laboratory accreditation is a voluntary process. However, laboratories are not opting for such accreditations as this may increase investment (to meet the required standards of accreditation).

Independent controls accounted for the largest share of the molecular quality controls market in 2020

Based on product, the molecular quality control market is segmented into Independent Controls and Instrument Specific Controls. The Independent control segment accounted for the largest share of the molecular quality control market in 2020. The increasing number of accredited laboratories and mandates for the use of quality controls from regulatory bodies to ensure the accuracy of diagnostic test results are driving the growth of the molecular quality control products market.

Single-analyte controls to account for the largest share of the market during the forecast period

Based on analyte type, the molecular quality controls market is segmented into single-analyte controls and multi-analyte controls. Single-analyte controls dominated the molecular quality controls market in 2020 due to the significant use of singleplex assays in hospitals and the advantages associated with the use of single-analyte controls, such as simple analysis & interpretation and low risk of cross-reactivity.

Infectious Disease Diagnostic to account for the largest share of the market during the forecast period

Based on application, the molecular quality controls market is segmented into infectious disease diagnostics, oncology testing, genetic testing, and other applications. The infectious disease diagnostics segment accounted for the largest share of the molecular quality controls market in 2020. The large share of this segment is attributed to the development of advanced assays for infectious diseases, a significant increase in the prevalence of infectious diseases, and the rising awareness about the effective use of molecular diagnostic technologies to control the occurrence and spread of infectious diseases.

Diagnostic Laboratories to account for the largest share of the market during the forecast period

The key end users of molecular quality controls studied in this report include diagnostic laboratories, hospitals, IVD Manufacturers and CROs Academic & Research Institutes, and other end users. The Diagnostic Laboratories segment accounted for the largest share of the molecular quality control market in 2020, increasing number of accredited diagnostic laboratories to provide growth opportunities in the coming years.

The APAC molecular quality controls market is projected to grow at the highest rate during the forecast period.

The molecular quality controls market is segmented into five major regions, namely, North America, Europe, Asia Pacific, Latin America, and the Middle East & Africa. In 2020, North America was the largest regional market for molecular quality controls due to the developed healthcare system in the US and Canada, the presence of many leading molecular quality control product manufacturers in the region, and the easy accessibility to technologically advanced products in the region. However, the market in the Asia Pacific is estimated to grow at the highest CAGR during the forecast period. The presence of emerging economies such as China and India and the significant demand for high-quality and accurate diagnostic tests from the large patient population in this region are the major factors supporting the growth of the Asia Pacific molecular quality controls market.

Molecular Quality Controls Market by Region

To know about the assumptions considered for the study, download the pdf brochure

Key Market Players

The prominent players in the molecular quality controls market F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific, Inc. (US), Randox Laboratories Ltd. (UK), LGC Limited (UK), Abbott Laboratories (US), Fortress Diagnostics (UK), SERO AS (Norway), Anchor Molecular (US), Ortho-Clinical Diagnostics, Inc. (US), Quidel Corporation (US), Sun Diagnostics, LLC (US), Seegene Inc. (South Korea), ZeptoMetrix, LLC (US), Qnostics (UK), Bio-Techne Corporation (US), Microbiologics, Inc. (US), Microbix Biosystems Inc. (Canada), SpeeDx Pty. Ltd. (Australia), Maine Molecular Quality Controls, Inc. (US), and Grifols, S.A. (Spain).

Get online access to the report on the World's First Market Intelligence Cloud

  • Easy to Download Historical Data & Forecast Numbers
  • Company Analysis Dashboard for high growth potential opportunities
  • Research Analyst Access for customization & queries
  • Competitor Analysis with Interactive dashboard
  • Latest News, Updates & Trend analysis
Request Sample

Scope of the Report

Report Metric

Details

Market size available for years

2019–2026

Base year considered

2020

Forecast period

2021–2026

Forecast units

Values (USD Million)

Segments covered

Product, Analyte Type, Application, End User, and Region

Geographies covered

North America, Europe, APAC, Latin America and Middle east and Africa

Companies covered

F. Hoffmann-La Roche Ltd. (Switzerland), Bio-Rad Laboratories, Inc. (US), Thermo Fisher Scientific, Inc. (US), Randox Laboratories Ltd. (UK), LGC Limited (UK), Abbott Laboratories (US), Fortress Diagnostics (UK), SERO AS (Norway), Anchor Molecular (US), Ortho-Clinical Diagnostics, Inc. (US), Quidel Corporation (US), Sun Diagnostics, LLC (US), Seegene Inc. (South Korea), ZeptoMetrix, LLC (US), Qnostics (UK), Bio-Techne Corporation (US), Microbiologics, Inc. (US), Microbix Biosystems Inc. (Canada), SpeeDx Pty. Ltd. (Australia), Maine Molecular Quality Controls, Inc. (US), and Grifols, S.A. (Spain).

By product, the molecular quality controls market is segmented as follows:

  • Independent Controls
  • Instrument-specific Controls, By Technology
    • PCR
    • DNA Sequencing & NGS
    • Other Technologies 

By Analyte type, the molecular quality controls market is segmented as follows:

  • Single-analyte Controls
  • Multi-analyte Controls

By Application, the molecular quality controls market is segmented as follows:

  • Infectious Diseases Diagnostics
  • Oncology Testing
  • Genetic Testing
  • Other Applications

By End User, the molecular quality controls market is segmented as follows:

  • Diagnostic Laboratories
  • Hospitals
  • IVD Manufacturers & CROs
  • Academic and Research Institutes 
  • Other End Users

By Region, the molecular quality controls market is segmented as follows:

  • North America
    • US
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Russia
    • ROE
  • Asia Pacific
    • China
    • Japan
    • India
    • RoPAC
  • Latin America
  • Middle East & Africa

Recent Developments

  • In June 2021, SeraCare partnered with the International Quality Network for Pathology (IQN Path) (Luxembourg) to develop, manufacture, and supply a range of highly characterized cell line genomic DNA and formalin-fixed, paraffin-embedded (FFPE) standards with confirmed low, mid, and high levels of mutational burden within their exome regions
  • In May 2021, Bio-Rad entered a global partnership with Roche Diagnostics (Switzerland) to provide its customers access to a complete line of InteliQ products and Unity QC data management solutions along with customer training and support services.
  • In 2020, Abbott Laboratories invested USD 2.4 billion in R&D, of which USD 10.80 billion was invested in developing technologically advanced diagnostic products to strengthen its product portfolio.

Frequently Asked Questions (FAQ):

To speak to our analyst for a discussion on the above findings, click Speak to Analyst

TABLE OF CONTENTS

1 INTRODUCTION (Page No. - 29)
    1.1 OBJECTIVES OF THE STUDY
    1.2 MARKET DEFINITION
           1.2.1 INCLUSIONS & EXCLUSIONS OF THE STUDY
    1.3 MARKET SCOPE
           1.3.1 MARKETS COVERED
           1.3.2 YEARS CONSIDERED FOR THE STUDY
    1.4 CURRENCY
           TABLE 1 STANDARD CURRENCY CONVERSION RATES
    1.5 LIMITATIONS
    1.6 STAKEHOLDERS
    1.7 SUMMARY OF CHANGES

2 RESEARCH METHODOLOGY (Page No. - 35)
    2.1 RESEARCH DATA
           FIGURE 1 RESEARCH DESIGN
           2.1.1 SECONDARY DATA
                    2.1.1.1 Key data from secondary sources
           2.1.2 SECONDARY RESEARCH
           2.1.3 PRIMARY DATA
                    FIGURE 2 PRIMARY SOURCES
                    2.1.3.1 Key data from primary sources
                               FIGURE 3 INSIGHTS FROM INDUSTRY EXPERTS
                    2.1.3.2 Breakdown of primary sources
                               FIGURE 4 BREAKDOWN OF PRIMARY INTERVIEWS: SUPPLY-SIDE AND DEMAND-SIDE PARTICIPANTS
                               FIGURE 5 PRIMARY SOURCES
    2.2 MARKET SIZE ESTIMATION
           2.2.1 BOTTOM-UP APPROACH
                    FIGURE 6 MOLECULAR QUALITY CONTROLS MARKET: BOTTOM-UP APPROACH
           2.2.2 TOP-DOWN APPROACH
                    FIGURE 7 MOLECULAR QUALITY CONTROLS MARKET: TOP-DOWN APPROACH
                    FIGURE 8 SUPPLY-SIDE MARKET SIZE ESTIMATION: REVENUE SHARE ANALYSIS
                    FIGURE 9 SUPPLY-SIDE MARKET SIZE ESTIMATION: MOLECULAR QUALITY CONTROLS MARKET (2020)
                    FIGURE 10 MARKET SIZE ESTIMATION: PARENT MARKET
                    FIGURE 11 CAGR PROJECTIONS: SUPPLY-SIDE ANALYSIS
                    FIGURE 12 CAGR PROJECTIONS FROM THE ANALYSIS OF DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES OF THE MOLECULAR QUALITY CONTROLS MARKET (2021–2026)
    2.3 MARKET BREAKDOWN AND DATA TRIANGULATION
           FIGURE 13 DATA TRIANGULATION METHODOLOGY
    2.4 MARKET SHARE ESTIMATION
    2.5 ASSUMPTIONS FOR THE STUDY
    2.6 RISK ASSESSMENT
           TABLE 2 RISK ASSESSMENT: MOLECULAR QUALITY CONTROLS MARKET
    2.7 COVID-19 HEALTH ASSESSMENT
    2.8 COVID-19 ECONOMIC ASSESSMENT
    2.9 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO
           FIGURE 14 CRITERIA IMPACTING THE GLOBAL ECONOMY
           FIGURE 15 RECOVERY SCENARIO OF THE GLOBAL ECONOMY
    2.10 ASSESSMENT OF THE IMPACT OF COVID-19 ON THE ECONOMIC SCENARIO IN THE MOLECULAR QUALITY CONTROLS MARKET

3 EXECUTIVE SUMMARY (Page No. - 54)
    FIGURE 16 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2021 VS. 2026 (USD MILLION)
    FIGURE 17 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2021 VS. 2026 (USD MILLION)
    FIGURE 18 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2021 VS. 2026 (USD MILLION)
    FIGURE 19 MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2021 VS. 2026 (USD MILLION)
    FIGURE 20 GEOGRAPHICAL SNAPSHOT OF THE MOLECULAR QUALITY CONTROLS MARKET

4 PREMIUM INSIGHTS (Page No. - 58)
    4.1 MOLECULAR QUALITY CONTROLS: MARKET OVERVIEW
           FIGURE 21 INCREASING GOVERNMENT FUNDING TO SUPPORT GENOMICS PROJECTS TO DRIVE MARKET GROWTH
    4.2 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT
           FIGURE 22 INSTRUMENT-SPECIFIC CONTROLS SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD (2021–2026)
    4.3 APAC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION AND COUNTRY (2020)
           FIGURE 23 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT ACCOUNTED FOR THE LARGEST SHARE OF THE APAC MOLECULAR QUALITY CONTROLS MARKET IN 2020
    4.4 MOLECULAR QUALITY CONTROLS MARKET: GEOGRAPHIC MIX
           FIGURE 24 CHINA TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
    4.5 MOLECULAR QUALITY CONTROLS MARKET: DEVELOPED VS. DEVELOPING MARKETS
           FIGURE 25 DEVELOPING MARKETS TO REGISTER HIGHER GROWTH RATE DURING THE FORECAST PERIOD

5 MARKET OVERVIEW (Page No. - 63)
    5.1 INTRODUCTION
           FIGURE 26 MOLECULAR QUALITY CONTROLS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES, AND CHALLENGES
           5.1.1 DRIVERS
                    5.1.1.1 Increasing number of accredited clinical laboratories
                               FIGURE 27 NUMBER OF LABORATORIES THAT RECEIVED CLIA ACCREDITATION, BY ACCREDITATION ORGANIZATION (2021)
                    5.1.1.2 Growing adoption of third-party quality controls
                    5.1.1.3 Increasing government funding to support genomics projects
                               TABLE 3 GOVERNMENT FUNDING TO SUPPORT GENOMICS
                    5.1.1.4 Increasing demand for personalized medicines and declining costs of sequencing procedures
                               FIGURE 28 COST OF SEQUENCING PROCEDURES, 2016-2021
                    5.1.1.5 Increasing prevalence of infectious diseases, cancer, & genetic diseases
                               FIGURE 29 GLOBAL CANCER INCIDENCE, 2020 VS. 2024
                    5.1.1.6 Rising demand for external quality assessment support
           5.1.2 RESTRAINTS
                    5.1.2.1 Additional costs involved in quality control and budget constraints in hospitals and laboratories
                    5.1.2.2 Unfavorable reimbursement scenario for molecular tests
           5.1.3 OPPORTUNITIES
                    5.1.3.1 Rising demand for multi-analyte controls
                    5.1.3.2 Growth opportunities in emerging countries
           5.1.4 CHALLENGES
                    5.1.4.1 Lack of mandatory regulations for clinical laboratory accreditation in several emerging countries
                    5.1.4.2 Changing regulatory framework

6 INDUSTRY INSIGHTS (Page No. - 72)
    6.1 INDUSTRY TRENDS
           6.1.1 INCREASING DEMAND FOR THIRD-PARTY INDEPENDENT QUALITY CONTROLS
                    TABLE 4 THIRD-PARTY INDEPENDENT QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS
           6.1.2 CONSOLIDATION OF LABORATORIES
    6.2 PRICING ANALYSIS
           TABLE 5 PRICING ANALYSIS OF MOLECULAR QUALITY CONTROL PRODUCTS (2021)
           FIGURE 30 MOLECULAR QUALITY CONTROL PATENT PUBLICATION TRENDS (JANUARY 2012-JANUARY 2022)
           FIGURE 31 MOLECULAR QUALITY CONTROLS: TOP 10 COMPANIES WITH THE HIGHEST PATENT APPLICATIONS (2011-2020)
           FIGURE 32 MOLECULAR QUALITY CONTROLS: TOP 10 PATENT OWNERS (2011-2020)
    6.3 VALUE CHAIN ANALYSIS
           FIGURE 33 VALUE CHAIN ANALYSIS
    6.4 SUPPLY CHAIN ANALYSIS
           FIGURE 34 SUPPLY CHAIN ANALYSIS
    6.5 ECOSYSTEM ANALYSIS
    6.6 PORTER’S FIVE FORCES ANALYSIS
           TABLE 6 MOLECULAR QUALITY CONTROLS MARKET: PORTER’S FIVE FORCES ANALYSIS
           6.6.1 THREAT OF NEW ENTRANTS
           6.6.2 THREAT OF SUBSTITUTES
           6.6.3 BARGAINING POWER OF BUYERS
           6.6.4 BARGAINING POWER OF SUPPLIERS
           6.6.5 COMPETITIVE RIVALRY AMONG EXISTING PLAYERS
    6.7 REGULATORY ANALYSIS
           6.7.1 NORTH AMERICA
                    6.7.1.1 US
                               TABLE 7 US: CLASSIFICATION OF QUALITY CONTROL MATERIAL
                    6.7.1.2 Canada
           6.7.2 EUROPE
                    TABLE 8 EUROPE: ACCREDITATION BODIES FOR MEDICAL LABORATORIES
           6.7.3 ASIA PACIFIC
                    6.7.3.1 Japan
                    6.7.3.2 China
                    6.7.3.3 India
    6.8 TRENDS & DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESS
           FIGURE 35 MOLECULAR QUALITY CONTROLS MARKET: TRENDS & DISRUPTIONS AFFECTING CUSTOMERS’ BUSINESSES
           6.8.1 COVID-19 IMPACT ANALYSIS

7 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT (Page No. - 86)
    7.1 INTRODUCTION
           FIGURE 36 INDEPENDENT CONTROLS SEGMENT TO DOMINATE THE MOLECULAR QUALITY CONTROLS MARKET IN 2026
           TABLE 9 QUALITY CONTROLS FOR MOLECULAR DIAGNOSTICS OFFERED BY KEY MARKET PLAYERS
           TABLE 10 MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
    7.2 INDEPENDENT CONTROLS
           7.2.1 A WIDE RANGE OF APPLICATIONS AND REDUCTIONS IN OPERATIONAL COSTS HAVE BOOSTED THE ADOPTION OF INDEPENDENT CONTROLS
                    TABLE 11 INDEPENDENT MOLECULAR QUALITY CONTROLS OFFERED BY KEY MARKET PLAYERS
                    TABLE 12 INDEPENDENT MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    7.3 INSTRUMENT-SPECIFIC CONTROLS
           TABLE 13 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           TABLE 14 INSTRUMENT-SPECIFIC MOLECULAR QUALITY CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
           7.3.1 POLYMERASE CHAIN REACTION (PCR)
                    7.3.1.1 Growing use of PCR in proteomics and genomics is a major factor driving market growth
                               TABLE 15 PCR MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.2 DNA SEQUENCING & NGS
                    7.3.2.1 Advancements in sequencing technologies to support market growth
                               TABLE 16 DNA SEQUENCING & NGS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
           7.3.3 OTHER TECHNOLOGIES
                    TABLE 17 OTHER TECHNOLOGIES MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

8 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE (Page No. - 96)
    8.1 INTRODUCTION
           FIGURE 37 SINGLE-ANALYTE CONTROLS SEGMENT DOMINATES THE MOLECULAR QUALITY CONTROLS MARKET
           TABLE 18 MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
    8.2 SINGLE-ANALYTE CONTROLS
           8.2.1 SIGNIFICANT USE OF SINGLEPLEX ASSAYS IN HOSPITALS IS A KEY FACTOR DRIVING MARKET GROWTH
                    TABLE 19 SINGLE-ANALYTE MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
    8.3 MULTI-ANALYTE CONTROLS
           8.3.1 INCREASING PREFERENCE FOR MULTI-ANALYTE CONTROLS TO FUEL MARKET GROWTH
                    TABLE 20 EXAMPLES OF MULTI-ANALYTE CONTROLS
                    TABLE 21 MULTI-ANALYTE MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)

9 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION (Page No. - 101)
    9.1 INTRODUCTION
           FIGURE 38 INFECTIOUS DISEASE DIAGNOSTICS SEGMENT TO DOMINATE THE MOLECULAR QUALITY CONTROLS MARKET DURING THE FORECAST PERIOD
           TABLE 22 MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
    9.2 INFECTIOUS DISEASE DIAGNOSTICS
           9.2.1 GROWING FOCUS ON PERSONALIZED MEDICINE TO DRIVE MARKET GROWTH
                    TABLE 23 NUMBER OF COVID-19 CASES, BY COUNTRY (2021)
                    TABLE 24 MOLECULAR QUALITY CONTROLS MARKET FOR INFECTIOUS DISEASE DIAGNOSTICS, BY COUNTRY, 2019–2026 (USD MILLION)
    9.3 ONCOLOGY TESTING
           9.3.1 ONCOLOGY TESTING SEGMENT IS PROJECTED TO REGISTER THE HIGHEST CAGR DURING THE FORECAST PERIOD
                    TABLE 25 MOLECULAR QUALITY CONTROLS MARKET FOR ONCOLOGY TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
    9.4 GENETIC TESTING
           9.4.1 ADVANCEMENTS IN GENETIC TESTING TO DRIVE MARKET GROWTH
                    TABLE 26 MOLECULAR QUALITY CONTROLS MARKET FOR GENETIC TESTING, BY COUNTRY, 2019–2026 (USD MILLION)
    9.5 OTHER APPLICATIONS
           TABLE 27 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER APPLICATIONS, BY COUNTRY, 2019–2026 (USD MILLION)

10 MOLECULAR QUALITY CONTROLS MARKET, BY END USER (Page No. - 109)
     10.1 INTRODUCTION
           FIGURE 39 DIAGNOSTIC LABORATORIES SEGMENT TO REGISTER THE HIGHEST GROWTH IN THE FORECAST PERIOD
           TABLE 28 MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
     10.2 DIAGNOSTIC LABORATORIES
             10.2.1 INCREASING NUMBER OF ACCREDITED DIAGNOSTIC LABORATORIES TO PROVIDE GROWTH OPPORTUNITIES IN THE COMING YEARS
                        TABLE 29 MOLECULAR QUALITY CONTROLS MARKET FOR DIAGNOSTIC LABORATORIES, BY COUNTRY, 2019–2026 (USD MILLION)
     10.3 HOSPITALS
             10.3.1 GROWING PATIENT VOLUME IS DRIVING THE ADOPTION OF MOLECULAR QUALITY CONTROLS AMONG HOSPITALS
                        TABLE 30 MOLECULAR QUALITY CONTROLS MARKET FOR HOSPITALS, BY COUNTRY, 2019–2026 (USD MILLION)
     10.4 IVD MANUFACTURERS & CONTRACT RESEARCH ORGANIZATIONS
             10.4.1 ADVANCEMENTS IN MOLECULAR TECHNOLOGIES TO SUPPORT MARKET GROWTH
                        TABLE 31 MOLECULAR QUALITY CONTROLS MARKET FOR IVD MANUFACTURERS & CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2019–2026 (USD MILLION)
     10.5 ACADEMIC & RESEARCH INSTITUTES
             10.5.1 RISING FOCUS ON ACCURATE RESEARCH RESULTS TO DRIVE MARKET GROWTH
                        TABLE 32 MOLECULAR QUALITY CONTROLS MARKET FOR ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2019–2026 (USD MILLION)
     10.6 OTHER END USERS
             TABLE 33 MOLECULAR QUALITY CONTROLS MARKET FOR OTHER END USERS, BY COUNTRY, 2019–2026 (USD MILLION)

11 MOLECULAR QUALITY CONTROLS MARKET, BY REGION (Page No. - 117)
     11.1 INTRODUCTION
             TABLE 34 MOLECULAR QUALITY CONTROLS MARKET, BY REGION, 2019–2026 (USD MILLION)
     11.2 NORTH AMERICA
             FIGURE 40 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT
             TABLE 35 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 36 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 37 NORTH AMERICA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 38 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
             TABLE 39 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 40 NORTH AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.1 US
                        11.2.1.1 Increasing CLIA accreditation for clinical laboratories is driving the market for molecular quality controls in the US
                                     FIGURE 41 US: NUMBER OF LABORATORIES WITH CLIA ACCREDITATION, BY ORGANIZATION (2018)
                                     TABLE 41 US: KEY MACROINDICATORS
                                     TABLE 42 US: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 43 US: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 44 US: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 45 US: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 46 US: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.2.2 CANADA
                        11.2.2.1 Canada has a well-established and well-funded biomedical research sector
                                     TABLE 47 CANADA: KEY MACROINDICATORS
                                     TABLE 48 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 49 CANADA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 50 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 51 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 52 CANADA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.3 EUROPE
             FIGURE 42 EUROPE: CANCER PREVALENCE, BY COUNTRY
             TABLE 53 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 54 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 55 EUROPE: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 56 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
             TABLE 57 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 58 EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.1 GERMANY
                        11.3.1.1 Increasing number of certified laboratories and the rising volume of high-quality tests performed by these laboratories to support market growth in Germany
                                     TABLE 59 GERMANY: KEY MACROINDICATORS
                                     TABLE 60 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 61 GERMANY: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 62 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 63 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 64 GERMANY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.2 FRANCE
                        11.3.2.1 Increasing prevalence of infectious diseases and growing demand for early diagnosis to drive market growth
                                     TABLE 65 FRANCE: KEY MACROINDICATORS
                                     TABLE 66 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 67 FRANCE: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 68 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 69 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 70 FRANCE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.3 UK
                        11.3.3.1 Growth in the life science industry and increased research to drive market growth in the UK
                                     TABLE 71 UK: KEY MACROINDICATORS
                                     TABLE 72 UK: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 73 UK: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 74 UK: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 75 UK: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 76 UK: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.4 ITALY
                        11.3.4.1 Growing disease prevalence to drive the demand for better and more accurate disease diagnosis in Italy
                                     TABLE 77 ITALY: KEY MACROINDICATORS
                                     TABLE 78 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 79 ITALY: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 80 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 81 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 82 ITALY: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.5 SPAIN
                        11.3.5.1 Increasing demand for prenatal and genetic testing and rising focus on laboratory consolidation to support market growth in Spain
                                     TABLE 83 SPAIN: KEY MACROINDICATORS
                                     TABLE 84 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 85 SPAIN: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 86 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 87 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 88 SPAIN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.6 RUSSIA
                        11.3.6.1 Increasing acceptance of molecular diagnostics-based personalized medicine to drive market growth
                                     TABLE 89 RUSSIA: DISEASE STATISTICS (2020)
                                     TABLE 90 RUSSIA: POPULATION AND CANCER STATISTICS
                                     TABLE 91 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 92 RUSSIA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 93 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 94 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 95 RUSSIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.3.7 REST OF EUROPE
                        TABLE 96 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 97 REST OF EUROPE: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 98 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                        TABLE 99 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 100 REST OF EUROPE: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.4 ASIA PACIFIC
             FIGURE 43 ASIA PACIFIC: CANCER PREVALENCE
             FIGURE 44 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET SNAPSHOT
             TABLE 101 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY COUNTRY, 2019–2026 (USD MILLION)
             TABLE 102 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
             TABLE 103 ASIA PACIFIC: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
             TABLE 104 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
             TABLE 105 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
             TABLE 106 ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.1 JAPAN
                        11.4.1.1 Well-developed healthcare system and the rising demand for improvements in the quality of IVD test results to drive market growth in Japan
                                     TABLE 107 JAPAN: KEY MACROINDICATORS
                                     TABLE 108 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 109 JAPAN: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 110 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 111 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 112 JAPAN: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.2 CHINA
                        11.4.2.1 Growing access to modern healthcare and government support to boost the market growth in China
                                     TABLE 113 CHINA: KEY MACROINDICATORS
                                     TABLE 114 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 115 CHINA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 116 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 117 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 118 CHINA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.3 INDIA
                        11.4.3.1 Rising need to secure NABL accreditations to drive the demand for quality controls in India
                                     FIGURE 45 INDIA: INCREASING NUMBER OF LABS WITH NABL ACCREDITATIONS, 2012–2020
                                     TABLE 119 INDIA: KEY MACROINDICATORS
                                     TABLE 120 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                                     TABLE 121 INDIA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                                     TABLE 122 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                                     TABLE 123 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                                     TABLE 124 INDIA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
             11.4.4 REST OF ASIA PACIFIC
                        TABLE 125 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 126 REST OF ASIA PACIFIC: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 127 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                        TABLE 128 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 129 REST OF ASIA PACIFIC: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.5 LATIN AMERICA
             11.5.1 RISING INCIDENCE OF SEVERAL INFECTIOUS DISEASES TO DRIVE MARKET GROWTH
                        TABLE 130 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 131 LATIN AMERICA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 132 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                        TABLE 133 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 134 LATIN AMERICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)
     11.6 MIDDLE EAST & AFRICA
             11.6.1 GROWING GOVERNMENT INITIATIVES TO IMPROVE HEALTHCARE INFRASTRUCTURE TO DRIVE MARKET GROWTH
                        TABLE 135 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY PRODUCT, 2019–2026 (USD MILLION)
                        TABLE 136 MIDDLE EAST & AFRICA: INSTRUMENT-SPECIFIC CONTROLS MARKET, BY TECHNOLOGY, 2019–2026 (USD MILLION)
                        TABLE 137 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY ANALYTE TYPE, 2019–2026 (USD MILLION)
                        TABLE 138 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY APPLICATION, 2019–2026 (USD MILLION)
                        TABLE 139 MIDDLE EAST & AFRICA: MOLECULAR QUALITY CONTROLS MARKET, BY END USER, 2019–2026 (USD MILLION)

12 COMPETITIVE LANDSCAPE (Page No. - 171)
     12.1 MARKET OVERVIEW
     12.2 KEY PLAYER STRATEGIES
     12.3 REVENUE SHARE ANALYSIS OF THE TOP MARKET PLAYERS
     12.4 MARKET RANKING ANALYSIS
             FIGURE 47 RANK OF COMPANIES IN THE GLOBAL MOLECULAR QUALITY CONTROLS MARKET (2020)
     12.5 COMPETITIVE LEADERSHIP MAPPING
             12.5.1 STARS
             12.5.2 EMERGING LEADERS
             12.5.3 PERVASIVE PLAYERS
             12.5.4 PARTICIPANTS
                        FIGURE 48 MOLECULAR QUALITY CONTROLS MARKET: COMPETITIVE LEADERSHIP MAPPING (2020)
     12.6 COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020)
             12.6.1 PROGRESSIVE COMPANIES
             12.6.2 STARTING BLOCKS
             12.6.3 RESPONSIVE COMPANIES
             12.6.4 DYNAMIC COMPANIES
                        FIGURE 49 MOLECULAR QUALITY CONTROLS MARKET: COMPETITIVE LEADERSHIP MAPPING FOR START-UPS/SMES (2020)
     12.7 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS
             FIGURE 50 PRODUCT AND REGIONAL FOOTPRINT ANALYSIS OF THE TOP PLAYERS IN THE MOLECULAR QUALITY CONTROLS MARKET
     12.8 COMPANY GEOGRAPHIC FOOTPRINT
             12.8.1 GEOGRAPHIC REVENUE MIX: KEY PLAYERS
                        TABLE 140 COMPANY END-USER FOOTPRINT (20 COMPANIES)
                        TABLE 141 COMPANY REGIONAL FOOTPRINT (20 COMPANIES)
     12.9 COMPETITIVE SITUATION AND TRENDS
             12.9.1 MOLECULAR QUALITY CONTROLS MARKET: PRODUCT LAUNCHES & REGULATORY APPROVALS
                        TABLE 142 KEY PRODUCT LAUNCHES AND REGULATORY APPROVALS
             12.9.2 MOLECULAR QUALITY CONTROLS MARKET: KEY DEALS
                        TABLE 143 KEY DEALS

13 COMPANY PROFILES (Page No. - 190)
     13.1 KEY PLAYERS
(Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats))* 
             13.1.1 LGC LIMITED
                        TABLE 144 LGC LIMITED: BUSINESS OVERVIEW
                        FIGURE 51 LCG LIMITED: COMPANY SNAPSHOT (2021)
             13.1.2 THERMO FISHER SCIENTIFIC
                        TABLE 145 THERMO FISHER SCIENTIFIC: BUSINESS OVERVIEW
                        FIGURE 52 THERMO FISHER SCIENTIFIC: COMPANY SNAPSHOT (2020)
             13.1.3 BIO-RAD LABORATORIES, INC.
                        TABLE 146 BIO-RAD LABORATORIES, INC.: BUSINESS OVERVIEW
                        FIGURE 53 BIO-RAD LABORATORIES, INC.: COMPANY SNAPSHOT (2020)
             13.1.4 MICROBIOLOGICS, INC.
                        TABLE 147 MICROBIOLOGICS, INC.: BUSINESS OVERVIEW
             13.1.5 ABBOTT LABORATORIES
                        TABLE 148 ABBOTT LABORATORIES: BUSINESS OVERVIEW
                        FIGURE 54 ABBOTT LABORATORIES: COMPANY SNAPSHOT (2020)
     13.2 OTHER PLAYERS
             13.2.1 ROCHE DIAGNOSTICS
                        TABLE 149 ROCHE DIAGNOSTICS: BUSINESS OVERVIEW
                        FIGURE 55 ROCHE DIAGNOSTICS: COMPANY SNAPSHOT (2020)
             13.2.2 ZEPTOMETRIX, LLC
                        TABLE 150 ZEPTOMETRIX, LLC: BUSINESS OVERVIEW
             13.2.3 QUIDEL CORPORATION
                        TABLE 151 QUIDEL CORPORATION: BUSINESS OVERVIEW
                        FIGURE 56 QUIDEL CORPORATION: COMPANY SNAPSHOT (2021)
             13.2.4 QNOSTICS
                        TABLE 152 QNOSTICS: BUSINESS OVERVIEW
             13.2.5 MAINE MOLECULAR QUALITY CONTROLS, INC.
                        TABLE 153 MAINE MOLECULAR QUALITY CONTROLS, INC.: BUSINESS OVERVIEW
             13.2.6 RANDOX LABORATORIES LTD.
                        TABLE 154 RANDOX LABORATORIES LTD.: BUSINESS OVERVIEW
             13.2.7 BIO-TECHNE CORPORATION
                        TABLE 155 BIO-TECHNE CORPORATION: BUSINESS OVERVIEW
                        FIGURE 57 BIO-TECHNE CORPORATION: COMPANY SNAPSHOT (2021)
             13.2.8 FORTRESS DIAGNOSTICS
                        TABLE 156 FORTRESS DIAGNOSTICS: BUSINESS OVERVIEW
             13.2.9 MICROBIX BIOSYSTEMS
                        TABLE 157 MICROBIX BIOSYSTEMS: BUSINESS OVERVIEW
                        FIGURE 58 MICROBIX BIOSYSTEMS: COMPANY SNAPSHOT (2021)
             13.2.10 GRIFOLS, S.A.
                        TABLE 158 GRIFOLS, S.A.: BUSINESS OVERVIEW
                        FIGURE 59 GRIFOLS, S.A.: COMPANY SNAPSHOT (2020)
             13.2.11 ORTHO CLINICAL DIAGNOSTICS
                        TABLE 159 ORTHO CLINICAL DIAGNOSTICS: BUSINESS OVERVIEW
                        FIGURE 60 ORTHO CLINICAL DIAGNOSTICS: COMPANY SNAPSHOT (2020)
             13.2.12 ANCHOR MOLECULAR
                        TABLE 160 ANCHOR MOLECULAR: BUSINESS OVERVIEW
             13.2.13 SPEEDX PTY. LTD.
                        TABLE 161 SPEEDX PTY. LTD.: BUSINESS OVERVIEW
             13.2.14 SERO AS
                        TABLE 162 SERO AS: BUSINESS OVERVIEW
             13.2.15 SEEGENE INC.
                        TABLE 163 SEEGENE INC.: BUSINESS OVERVIEW
                        FIGURE 61 SEEGENE INC: COMPANY SNAPSHOT (2020)
*Details on Business Overview, Products Offered, Recent Developments, and MnM View (Key strengths/Right to Win, Strategic Choices Made, and Weaknesses and Competitive Threats) might not be captured in case of unlisted companies. 

14 APPENDIX (Page No. - 268)
     14.1 DISCUSSION GUIDE
     14.2 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL
     14.3 AVAILABLE CUSTOMIZATIONS
     14.4 RELATED REPORTS
     14.5 AUTHOR DETAILS

This research study involved the extensive use of secondary sources, directories, and databases to identify and collect information useful to the study on the molecular quality controls market. Primary sources were largely several industry experts from core and related industries and preferred suppliers, manufacturers, distributors, service providers, and technology developers. Primary sources also included standard and certification organizations from companies and organizations related to all segments of this industry’s value chain.

Secondary Research

In the secondary research process, various sources such as Bloomberg BusinessWeek, Forbes, and D&B were referred to, to identify and collect information useful for a technical, market-oriented, and commercial study of the molecular quality controls market. These secondary sources include annual reports, press releases & investor presentations of companies, Clinical and Laboratory Standards Institute (CLSI), Clinical Laboratory Improvement Amendments (CLIA), National Accreditation Board for Testing and Calibration Laboratories (NABL), Association for Molecular Pathology, International Organization for Standardization (ISO), World Health Organization (WHO), Quality Council of India (QCI), and College of American Pathologists (CAP). Secondary research was mainly used to obtain key information about the industry’s supply chain, the total pool of key players, market classification, and segmentation according to industry trends to the bottom-most level and regional markets. It was also used to obtain information about the key developments from a market-oriented perspective.

Primary Research

The molecular quality controls market comprises several stakeholders such as raw material suppliers, manufacturers of molecular quality controls, and regulatory organizations in the supply chain. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. The primary interviewees from the demand side include key opinion leaders in the IVD industry, hospital laboratories, clinical research laboratories, and academic institutes. The primary sources from the supply side include key opinion leaders, distributors, and molecular quality controls manufacturers. Various primary sources from both the supply and demand sides of the market were interviewed to obtain qualitative and quantitative information. Given below is the breakdown of primary respondents:

Molecular Quality Controls Market Size, and Share

To know about the assumptions considered for the study, download the pdf brochure

Market Size Estimation

Both top-down and bottom-up approaches have been used to estimate and validate the size of the molecular quality controls market and to estimate the size of various other dependent submarkets in the overall molecular quality controls market.

The research methodology used to estimate the market size includes the following details:

  • The market value of molecular quality controls for infectious disease diagnostics, oncology testing, and genetic testing applications have been extracted from the repository and validated through secondary and primary research.
  • The market shares of the infectious disease diagnostics, oncology testing, and genetic testing applications in the global molecular quality controls market were derived and added up to reach the market value.
  • This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives.
  • The bottom-up approach has been applied to different regions and other segments of the molecular quality controls market. All percentage shares, splits, and breakdowns have been determined by using secondary sources and verified through primary sources.
  • All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.
  • This data is consolidated and added with detailed inputs and analysis from MarketsandMarkets and presented in this report.

Approach to calculate the revenue of different players in the Molecular Quality Control market

In this report, the global molecular quality control market size was arrived at by using the revenue share analysis of leading players. For this purpose, major players in the market were identified, and their revenues from the molecular quality controls business were determined through various insights gathered during the primary and secondary research phases. Secondary research included the study of the annual and financial reports of the top market players. In contrast, primary research included extensive interviews with key opinion leaders, such as CEOs, directors, and key market players’ marketing executives.

Approach to derive the market size and estimate market growth

The total size of the molecular quality controls market was arrived at after data triangulation from three different approaches, as mentioned below. After each approach, the weighted average of the three approaches was taken based on the level of assumptions used in each approach.

Data Triangulation

After arriving at the overall market size from the market size estimation process explained above, the total market was split into several segments and subsegments. To complete the overall market engineering process and to arrive at the exact statistics for all segments and subsegments, data triangulation and market breakdown procedures were employed, wherever applicable. The data was triangulated by studying various factors and trends from both the demand and supply sides.

Report Objectives

  • To define, describe, segment, and forecast the global molecular quality controls market by product, analyte type, application, end user, and region
  • To provide detailed information about the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
  • To strategically analyze micromarkets1 with respect to individual growth trends, prospects, and contributions to the overall molecular quality controls market
  • To analyze market opportunities for stakeholders and provide details of the competitive landscape for key market players
  • To forecast the size of the market segments in five major regions, namely, North America, Europe, Asia Pacific (APAC), Latin America, and the Middle East & Africa
  • To profile the key players and comprehensively analyze their core competencies2 in terms of key market developments, product portfolios, and financials
  • To track and analyze competitive developments such as acquisitions, agreements, partnerships, collaborations, product launches, and expansions in the molecular quality controls market

Available Customizations

With the given market data, MarketsandMarkets offers customizations as per your company’s specific needs. The following customization options are available for the report:

Product Analysis

  • Product Matrix: Detailed comparison of the product portfolios of the top companies

Geographic Analysis

  • Further breakdown of the Rest of Asia Pacific molecular quality controls market into South Korea, Australia, New Zealand, and other countries
  • Further breakdown of the Rest of Europe molecular quality controls market into Belgium, the Netherlands, Switzerland, and other countries
  • Further breakdown of the Latin American molecular quality controls market into Brazil, Mexico, and the Rest of Latin America.
Report Code
MD 6900
Published ON
Feb, 2022
Choose License Type
BUY NOW
ADJACENT MARKETS
REQUEST BUNDLE REPORTS
  • SHARE
X
Request Customization
Speak to Analyst
Speak to Analyst
OR FACE-TO-FACE MEETING
PERSONALIZE THIS RESEARCH
  • Triangulate with your Own Data
  • Get Data as per your Format and Definition
  • Gain a Deeper Dive on a Specific Application, Geography, Customer or Competitor
  • Any level of Personalization
REQUEST A FREE CUSTOMIZATION
LET US HELP YOU!
  • What are the Known and Unknown Adjacencies Impacting the Molecular Quality Controls Market
  • What will your New Revenue Sources be?
  • Who will be your Top Customer; what will make them switch?
  • Defend your Market Share or Win Competitors
  • Get a Scorecard for Target Partners
CUSTOMIZED WORKSHOP REQUEST
+1-888-600-6441
  • Call Us
  • +1-888-600-6441 (Corporate office hours)
  • +1-888-600-6441 (US/Can toll free)
  • +44-800-368-9399 (UK office hours)
CONNECT WITH US
ABOUT TRUST ONLINE
©2022 MarketsandMarkets Research Private Ltd. All rights reserved